The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended the granting of marketing authorization for Hympavzi (marstacimab) for treating bleeding episodes in people aged 12 years or older with severe hemophilia A and B. The drug is now pending a final decision from the European Commission. …
